On 22 February 2018, orphan designation (EU/3/18/1979) was granted by the European Commission to Bayer AG, Germany, for human monoclonal IgG2 antibody against tissue factor pathway inhibitor (also known as BAY 1093884) for the treatment of haemophilia A.
Human monoclonal IgG2 antibody against tissue factor pathway inhibitor
|Disease / condition||
Treatment of haemophilia A
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.